Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 13,506.00p on 17-12-2025 at 06:00:01
Change 0.00p 0%
Buy 14,000.00p
Sell 13,000.00p
Last Trade: Unknown 180,544.00 at 13,744.00p
Day's Volume: 0
Last Close: 13,506.00p
Open: 0.00p
ISIN: GB0009895292
Day's Range 0.00p - 0.00p
52wk Range: 9,574.00p - 14,206.00p
Market Capitalisation: £209.38b
VWAP: 0.00p
Shares in Issue: 1.55b

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 180,544 13,744.00p Negotiated Trade
OTC Trade
17:09:21 - 16-Dec-25
Sell* 957 13,506.00p SI Trade
Suspected SELL Trade
16:48:08 - 16-Dec-25
Sell* 1,079 13,506.00p SI Trade
16:37:54 - 16-Dec-25
Sell* 17,769 13,506.00p SI Trade
16:35:28 - 16-Dec-25
Sell* 2,550 13,506.00p SI Trade
16:35:28 - 16-Dec-25
Sell* 89 13,506.00p SI Trade
16:35:28 - 16-Dec-25
Sell* 37 13,506.00p SI Trade
16:35:27 - 16-Dec-25
Sell* 471 13,506.00p SI Trade
16:35:27 - 16-Dec-25
Sell* 611 13,506.00p SI Trade
16:35:27 - 16-Dec-25
Sell* 271 13,506.00p SI Trade
16:35:27 - 16-Dec-25
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
17th Dec 2025 (Wed) 13,506.00 13,506.00 13,506.00 13,506.00 0
16th Dec 2025 (Tue) 13,744.00 13,836.00 13,448.00 13,506.00 3,264,005
15th Dec 2025 (Mon) 13,412.00 13,638.00 13,376.00 13,612.00 2,467,612
12th Dec 2025 (Fri) 13,502.00 13,536.00 13,362.00 13,444.00 1,443,553
11th Dec 2025 (Thu) 13,618.00 13,686.00 13,488.00 13,596.00 1,284,513
10th Dec 2025 (Wed) 13,482.00 13,848.00 13,472.00 13,514.00 2,485,716
9th Dec 2025 (Tue) 13,758.00 13,794.00 13,568.00 13,592.00 1,232,388
8th Dec 2025 (Mon) 13,580.00 13,702.00 13,478.00 13,578.00 3,939,445
5th Dec 2025 (Fri) 13,560.00 13,688.00 13,542.00 13,592.00 1,500,908
4th Dec 2025 (Thu) 13,612.00 13,660.00 13,452.00 13,514.00 1,868,284
3rd Dec 2025 (Wed) 13,698.00 13,826.00 13,598.00 13,694.00 1,966,393
2nd Dec 2025 (Tue) 13,714.00 13,820.00 13,648.00 13,800.00 1,678,650
1st Dec 2025 (Mon) 13,966.00 14,092.00 13,800.00 13,836.00 1,952,001
28th Nov 2025 (Fri) 14,002.00 14,054.00 13,920.00 13,974.00 1,719,003
27th Nov 2025 (Thu) 14,070.00 14,158.00 13,940.00 14,012.00 1,037,045
26th Nov 2025 (Wed) 14,162.00 14,206.00 14,024.00 14,148.00 2,008,336
25th Nov 2025 (Tue) 13,874.00 14,140.00 13,852.00 14,100.00 2,168,716
24th Nov 2025 (Mon) 13,932.00 13,970.00 13,820.00 13,934.00 3,131,310
21st Nov 2025 (Fri) 13,508.00 13,836.00 13,508.00 13,820.00 3,044,642
20th Nov 2025 (Thu) 13,604.00 13,788.00 13,600.00 13,650.00 1,656,417
19th Nov 2025 (Wed) 13,560.00 13,742.00 13,506.00 13,596.00 1,594,092
18th Nov 2025 (Tue) 13,800.00 13,884.00 13,466.00 13,566.00 1,654,390
17th Nov 2025 (Mon) 13,530.00 13,658.00 13,520.00 13,592.00 1,324,376
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
16th Dec 2025 7:05 am RNS Subcutaneous Saphnelo approved in EU
16th Dec 2025 7:00 am RNS Enhertu approved in US for 1L HER2+ metastatic BC
4th Dec 2025 3:00 pm RNS Holding(s) in Company
1st Dec 2025 3:05 pm RNS Block listing Interim Review
1st Dec 2025 3:00 pm RNS Total Voting Rights
26th Nov 2025 7:00 am RNS Imfinzi approved in US for early gastric cancer
24th Nov 2025 7:00 am RNS AstraZeneca manufacturing investment in Maryland
20th Nov 2025 7:00 am RNS Koselugo (selumetinib) approved in the US
17th Nov 2025 3:00 pm RNS Holding(s) in Company
14th Nov 2025 11:00 am RNS Director/PDMR Shareholding
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

AstraZeneca's Saphnelo gets EU approval for self-administration

16th Dec 2025 09:53

(Alliance News) - AstraZeneca PLC on Tuesday said its drug Saphnelo, or anifrolumab, has been approved in the European Union as a new pre-filled pen for systemic lupus erythematosus. Read More

AstraZeneca and Daiichi Sankyo's enhertu gets US cancer approval

15th Dec 2025 20:46

(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer. Read More

Outgoing GSK CEO Emma Walmsley declares US best place to invest

11th Dec 2025 09:35

(Alliance News) - Outgoing GSK PLC Chief Executive Officer Emma Walmsley has said the US is the best place to invest, in the latest blow to Britain's pharmaceutical sector, after a raft of drugs firms have scrapped or paused plans to invest in the UK. Read More

Hutchmed drugs stay on NRDL; Tazverik added to new insurance list

8th Dec 2025 11:15

(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More

LONDON BROKER RATINGS: JPMorgan cuts M&G, UBS cuts Trainline

8th Dec 2025 09:39

(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More

See more Astrazeneca news
FTSE 100 Latest
Value9,684.79
Change0.00

Login to your account

Forgot Password?

Not Registered